Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Journal of Clinical Oncology Publishes Leukine(R) Study Demonstrating Positive Survival Outcomes in Patients with High-Risk Melanoma
July 15th, 2008
Bayer HealthCare Pharmaceuticals confirmed that results of a Phase II trial were published in the July 1 edition of the Journal of Clinical Oncology. The study showed that Leukine(R) (sargramostim) demonstrated a median overall survival of 65 months and increased mature dendritic cells in high-risk melanoma patients. Dendritic cells are special antigen-presenting cells that help the immune system recognize cancer cells and are the most effective antigen-presenting cells known. Study authors concluded that this increase in dendritic cell counts may also correlate with delayed recurrence of disease. "These data provide early signals that Leukine may offer clinical benefit...
Source: Cancer Weekly (2008-07-15)
|
